BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084 AND Treatment
122 results:

  • 1. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
    D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
    Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
    Lindemann K; Kildal W; Kleppe A; Tobin KAR; Pradhan M; Isaksen MX; Vlatkovic L; Danielsen HE; Kristensen GB; Askautrud HA
    Eur J Cancer; 2024 Mar; 200():113584. PubMed ID: 38330767
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.
    Bruchim I; Capasso I; Polonsky A; Meisel S; Salutari V; Werner H; Lorusso D; Scambia G; Fanfani F
    Expert Opin Ther Targets; 2024; 28(1-2):29-43. PubMed ID: 38327111
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies.
    Bani MA; Maulard A; Morice P; Chargari C; Genestie C
    Anticancer Res; 2024 Feb; 44(2):445-452. PubMed ID: 38307584
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Exploring Co-occurring pole Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
    Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
    Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
    Tang M; Yin S; Zeng H; Huang A; Huang Y; Hu Z; Shah AR; Zhang S; Li H; Chen G
    Cell Death Dis; 2024 Jan; 15(1):69. PubMed ID: 38238314
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Race, Prevalence of pole and POLD1 Alterations, and Survival Among Patients With Endometrial cancer.
    Zheng S; Donnelly ED; Strauss JB
    JAMA Netw Open; 2024 Jan; 7(1):e2351906. PubMed ID: 38231514
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
    Wong RW; Cheung ANY
    Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Characteristics and outcomes of surgically staged multiple classifier endometrial cancer.
    Bogani G; Betella I; Multinu F; Casarin J; GhezzI F; Sorbi F; VizziellI G; Petrillo M; Cianci S; Berretta R; PaolinI B; FanfanI F; De Vitis L; Scambia G; Mariani A; Colombo N; Raspagliesi F
    Eur J Surg Oncol; 2024 Jan; 50(1):107269. PubMed ID: 37984242
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Molecular-based classification of endometrial carcinoma in Northern Thailand: impact on prognosis and potential for implementation in resource-limited settings.
    Dankai W; Pongsuvareeyakul T; Phinyo P; Tejamai C; Teerapakpinyo C; Cheewakriangkrai C; Lekawanvijit S; Siriaunkgul S; Khunamornpong S
    BMC Womens Health; 2023 Nov; 23(1):605. PubMed ID: 37964201
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
    André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
    JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated pole variants.
    Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework.
    Bruno V; Betti M; D'Ambrosio L; Massacci A; Chiofalo B; Pietropolli A; Piaggio G; Ciliberto G; Nisticò P; Pallocca M; Buda A; Vizza E
    Int J Gynecol Cancer; 2023 Nov; 33(11):1708-1714. PubMed ID: 37875322
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
    Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
    [No Abstract]    [Full Text] [Related]  

  • 15. [Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types].
    Li LL; Li H; Li J; Zhang XB; Wang ZQ; Shen DH; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):733-741. PubMed ID: 37849254
    [No Abstract]    [Full Text] [Related]  

  • 16. PErsonalized treatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
    Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
    Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Molecular classification of endometrial carcinoma-a short summary for clinical use].
    Hiller GGR; Höhn AK; Mayr D; Brambs CE; Horn LC
    Pathologie (Heidelb); 2023 Nov; 44(6):392-400. PubMed ID: 37815668
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis.
    Luzarraga Aznar A; Bebia V; López-Gil C; Giraldo A; Montoya MP; Verges R; Jauregui A; Castellvi J; Pérez-Benavente A; Colás E; Gil-Moreno A; Cabrera S
    Int J Gynecol Cancer; 2023 Oct; 33(10):1564-1571. PubMed ID: 37726197
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Multisequence MRI-based radiomics model for predicting
    Lin Z; Gu W; Guo Q; Xiao M; Li R; Deng L; Li Y; Cui Y; Li H; Qiang J
    Br J Radiol; 2023 Nov; 96(1151):20221063. PubMed ID: 37660398
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.
    Yang Y; Wu SF; Bao W
    Int J Gynaecol Obstet; 2024 Feb; 164(2):436-459. PubMed ID: 37525501
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.